Developmental Toxicity Study of DL-4-Hydroxy-4-Phenylhexanamide (DL-HEPB) in Rats

Area of Science:

• Pharmacology and Toxicology
• Developmental Biology
• Neuroscience

Background:

• Established antiepileptic drugs pose risks to embryonic development, causing severe congenital abnormalities.
• DL-4-hydroxy-4-phenylhexanamide (DL-HEPB), a structurally distinct phenyl alcohol amide, demonstrates promising anticonvulsant activity.
• The developmental toxicity profile of DL-HEPB remains uncharacterized.

Purpose of the Study:

• To evaluate the teratogenic potential of DL-HEPB in a rodent model.
• To assess the safety of DL-HEPB during the critical period of organogenesis.

Main Methods:

• Pregnant Wistar rats were administered varying oral doses of DL-HEPB (0, 50, 100, 200 mg/kg) during organogenesis.
• Maternal weight gain and food consumption were monitored.
• Fetal examination included external, visceral, and skeletal assessments on gestation day 21.

Main Results:

• Maternal exposure to DL-HEPB resulted in decreased food consumption and body weight, without other signs of toxicity.
• No external, visceral, or skeletal malformations were observed in fetuses exposed to DL-HEPB up to 100 mg/kg.
• A low frequency of brain and kidney malformations occurred in fetuses exposed to 200 mg/kg DL-HEPB.

Conclusions:

• DL-HEPB exhibits a favorable developmental toxicity profile at doses up to 100 mg/kg.
• DL-HEPB represents a potential lead compound for developing novel anticonvulsants with reduced teratogenic risk compared to existing therapies.
• Further research is warranted to fully elucidate the safety and efficacy of DL-HEPB for epilepsy treatment.